Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 19 10 2020
revised: 19 01 2021
accepted: 21 01 2021
pubmed: 29 1 2021
medline: 24 9 2021
entrez: 28 1 2021
Statut: ppublish

Résumé

Cardiac radioablation is a novel treatment option for therapy-refractory ventricular tachycardia (VT) ineligible for catheter ablation. Three-dimensional clinical target volume (CTV) definition is a key step, and this complex interdisciplinary procedure includes VT-substrate identification based on electroanatomical mapping (EAM) and its transfer to the planning computed tomography (PCT). Benchmarking of this process is necessary for multicenter clinical studies such as the RAVENTA trial. For benchmarking of the RAVENTA trial, patient data (epicrisis, electrocardiogram, high-resolution EAM, contrast-enhanced cardiac computed tomography, PCT) of 3 cases were sent to 5 university centers for independent CTV generation, subsequent structure analysis, and consensus finding. VT substrates were first defined on multiple EAM screenshots/videos and manually transferred to the PCT. The generated structure characteristics were then independently analyzed (volume, localization, surface distance and conformity). After subsequent discussion, consensus structures were defined. VT substrate on the EAM showed visible variability in extent and localization for cases 1 and 2 and only minor variability for case 3. CTVs ranged from 6.7 to 22.9 cm Multicenter efficacy endpoint assessment of cardiac radioablation for therapy-refractory VT requires consistent CTV transfer methods from the EAM to the PCT. VT substrate definition and CTVs were comparable with current clinical practice. Remarkable differences regarding the degree of agreement of the CTV definition on the EAM and the PCT were noted, indicating a loss of agreement during the transfer process between EAM and PCT. Cardiac radioablation should be performed under well-defined protocols and in clinical trials with benchmarking and consensus forming.

Identifiants

pubmed: 33508373
pii: S0360-3016(21)00088-2
doi: 10.1016/j.ijrobp.2021.01.028
pii:
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

745-756

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Judit Boda-Heggemann (J)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: judit.boda-heggemann@umm.de.

Oliver Blanck (O)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Felix Mehrhof (F)

Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.

Floris Ernst (F)

University of Lübeck, Institute for Robotic and Cognitive Systems, Lübeck, Germany.

Daniel Buergy (D)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Jens Fleckenstein (J)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Erol Tülümen (E)

I. Medizinische Klinik, Universitätsklinikum Mannheim and German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany.

David Krug (D)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Frank-Andre Siebert (FA)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Adrian Zaman (A)

Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Anne K Kluge (AK)

Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.

Abdul Shokor Parwani (AS)

Med. Klinik m.S. Kardiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Nicolaus Andratschke (N)

Klinik für Radio-Onkologie, UniversitätsSpital Zürich, Zürich, CH.

Michael C Mayinger (MC)

Klinik für Radio-Onkologie, UniversitätsSpital Zürich, Zürich, CH.

Stefanie Ehrbar (S)

Klinik für Radio-Onkologie, UniversitätsSpital Zürich, Zürich, CH.

Ardan M Saguner (AM)

Universitäres Herzzentrum, UniversitätsSpital Zürich, Zürich, CH.

Eren Celik (E)

Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Wolfgang W Baus (WW)

Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Annina Stauber (A)

Klinik III für Kardiologie, Angiologie, Pneumologie und Internistische Intensivmedizin, Universitätsklinikum Köln, Köln, Germany.

Lena Vogel (L)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Achim Schweikard (A)

University of Lübeck, Institute for Robotic and Cognitive Systems, Lübeck, Germany.

Volker Budach (V)

Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.

Jürgen Dunst (J)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Leif-Hendrik Boldt (LH)

Med. Klinik m.S. Kardiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Hendrik Bonnemeier (H)

Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Boris Rudic (B)

I. Medizinische Klinik, Universitätsklinikum Mannheim and German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH